JP2020511674A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511674A5 JP2020511674A5 JP2019571199A JP2019571199A JP2020511674A5 JP 2020511674 A5 JP2020511674 A5 JP 2020511674A5 JP 2019571199 A JP2019571199 A JP 2019571199A JP 2019571199 A JP2019571199 A JP 2019571199A JP 2020511674 A5 JP2020511674 A5 JP 2020511674A5
- Authority
- JP
- Japan
- Prior art keywords
- drug complex
- biomarker
- sample
- tspan13
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 18
- 210000004027 cells Anatomy 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 11
- 229940079593 drugs Drugs 0.000 claims 11
- 102100012539 TSPAN13 Human genes 0.000 claims 8
- 101710014367 TSPAN13 Proteins 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 102000004329 Glial cell line-derived neurotrophic factor Human genes 0.000 claims 6
- 108090000821 Glial cell line-derived neurotrophic factor Proteins 0.000 claims 6
- 102100003775 PLXNA3 Human genes 0.000 claims 6
- 101710031494 PLXNA3 Proteins 0.000 claims 6
- 102100003867 SUSD6 Human genes 0.000 claims 6
- 101700073105 SUSD6 Proteins 0.000 claims 6
- 102100015652 BCL2L2 Human genes 0.000 claims 5
- 101710032376 BCL2L2-PABPN1 Proteins 0.000 claims 5
- 102100016551 PLK3 Human genes 0.000 claims 5
- 101700007079 PLK3 Proteins 0.000 claims 5
- 102100001417 C2CD5 Human genes 0.000 claims 4
- 101700024880 C2CD5 Proteins 0.000 claims 4
- 102100016403 DYNLT3 Human genes 0.000 claims 4
- 101710043676 DYNLT3 Proteins 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 102100020330 FAM214B Human genes 0.000 claims 3
- 101710007076 FAM214B Proteins 0.000 claims 3
- 108060008400 TOLLIP Proteins 0.000 claims 3
- 102100009464 TOLLIP Human genes 0.000 claims 3
- 102100020408 ZBTB7A Human genes 0.000 claims 3
- 101710006424 ZBTB7A Proteins 0.000 claims 3
- 102100015658 B4GALT7 Human genes 0.000 claims 2
- 101710025602 B4GALT7 Proteins 0.000 claims 2
- 102100013894 BCL2 Human genes 0.000 claims 2
- 108060000885 BCL2 Proteins 0.000 claims 2
- 102100010323 CHMP5 Human genes 0.000 claims 2
- 101700025808 CHMP5 Proteins 0.000 claims 2
- 102000012688 DDA1 Human genes 0.000 claims 2
- 108060002129 DDA1 Proteins 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 210000003097 Mucus Anatomy 0.000 claims 2
- 101700066464 NOL3 Proteins 0.000 claims 2
- 102100000793 NOL3 Human genes 0.000 claims 2
- 102100007296 PDLIM4 Human genes 0.000 claims 2
- 101710002932 PDLIM4 Proteins 0.000 claims 2
- 102100001941 SCOC Human genes 0.000 claims 2
- 108060007293 SCOC Proteins 0.000 claims 2
- 102100007163 SLC16A3 Human genes 0.000 claims 2
- 108091006516 SLC16A3 Proteins 0.000 claims 2
- 102100010008 TAF13 Human genes 0.000 claims 2
- 108060008045 TAF13 Proteins 0.000 claims 2
- 230000002424 anti-apoptotic Effects 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 230000010094 cellular senescence Effects 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims 1
- JKMWZKPAXZBYEH-JWHWKPFMSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3C(=N/NC=4SC5=CC=CC=C5N=4)/CCCC3=CC=2)S1 JKMWZKPAXZBYEH-JWHWKPFMSA-N 0.000 claims 1
- 101700066925 ARID2 Proteins 0.000 claims 1
- 102100001854 ARID2 Human genes 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 229920002395 Aptamer Polymers 0.000 claims 1
- 210000001742 Aqueous Humor Anatomy 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 102100015655 BCL2L1 Human genes 0.000 claims 1
- 101710032374 BCL2L1 Proteins 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 102100003767 CREBBP Human genes 0.000 claims 1
- 101710006045 CREBBP Proteins 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 210000000845 Cartilage Anatomy 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102100010095 EFNB3 Human genes 0.000 claims 1
- 108010044085 Ephrin-B3 Proteins 0.000 claims 1
- 210000003608 Feces Anatomy 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 210000004209 Hair Anatomy 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102100008555 ICE1 Human genes 0.000 claims 1
- 108060003849 ICE1 Proteins 0.000 claims 1
- 101700002093 MEIS1 Proteins 0.000 claims 1
- 102100010482 MEIS1 Human genes 0.000 claims 1
- 102100017712 MMD2 Human genes 0.000 claims 1
- 101710021356 MMD2 Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 201000002073 Miyoshi muscular dystrophy 2 Diseases 0.000 claims 1
- 210000000282 Nails Anatomy 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N Navitoclax Chemical group C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 241000283898 Ovis Species 0.000 claims 1
- 102100007102 PATZ1 Human genes 0.000 claims 1
- 101700055583 PATZ1 Proteins 0.000 claims 1
- 102100014461 PCIF1 Human genes 0.000 claims 1
- 101710009232 PCIF1 Proteins 0.000 claims 1
- 102100007624 PDS5B Human genes 0.000 claims 1
- 101700082301 PDS5B Proteins 0.000 claims 1
- 108060006309 PMEPA1 Proteins 0.000 claims 1
- 102100006819 PMEPA1 Human genes 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 102000030002 Prion Proteins Human genes 0.000 claims 1
- 108091000054 Prion Proteins Proteins 0.000 claims 1
- 102100012950 RAI14 Human genes 0.000 claims 1
- 101700042782 RAI14 Proteins 0.000 claims 1
- 102100005088 RHNO1 Human genes 0.000 claims 1
- 101700064018 RHNO1 Proteins 0.000 claims 1
- 101700021542 SMO Proteins 0.000 claims 1
- 102100015930 SMOX Human genes 0.000 claims 1
- 101700076839 SMOX Proteins 0.000 claims 1
- 102100004035 SPIN4 Human genes 0.000 claims 1
- 101700014744 SPIN4 Proteins 0.000 claims 1
- 210000003296 Saliva Anatomy 0.000 claims 1
- 210000000582 Semen Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000004243 Sweat Anatomy 0.000 claims 1
- 102100009532 TMEM87B Human genes 0.000 claims 1
- 101710013188 TMEM87B Proteins 0.000 claims 1
- 101710014598 TRDMT1 Proteins 0.000 claims 1
- 102100012966 TRDMT1 Human genes 0.000 claims 1
- 210000001138 Tears Anatomy 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 1
- 102100008031 UFM1 Human genes 0.000 claims 1
- 108060008772 UFM1 Proteins 0.000 claims 1
- 210000002700 Urine Anatomy 0.000 claims 1
- 102100005123 ZNHIT1 Human genes 0.000 claims 1
- 108060009673 ZNHIT1 Proteins 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004908 prostatic fluid Anatomy 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000002588 toxic Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Claims (20)
- 6個以上のポリペプチド、又はそれらをコードするmRNAを含むバイオマーカーパネルであって、ここで該パネルが少なくともバイオマーカーTSPAN13、GDNF、C2CD5、SUSD6、BCL2L2及びPLK3、又はそれらの変異体若しくは断片を細胞老化のバイオマーカーセットとして含む、バイオマーカーパネル。
- 前記セットが、更にCTLN、FAM214B、PATZ 1、PLXNA3、STAG1、TOLLIP、TRDMT1、ZBTB7A、ARID2、B4GALT7、CHMP5、CREBBP、DDA1, DYNLT3、EFNB3、ICE1、MEIS1、NOL3、PCIF1、PDLIM4, PDS5B、RAI14、RHNO1、SCOC、SLC16A3、SMO、SPIN4、TAF13、TMEM87B、UFM1及びZNHIT1、又はそれらの変異体若しくは断片からなる群から選択される、1以上のバイオマーカーを含む、請求項1に記載のバイオマーカーパネル。
- 前記セットが、バイオマーカーTSPAN13、GDNF、C2CD5、SUSD6、BCL2L2、PLK3、並びに、DYNLT3及びPLXNA3の1つ若しくは両方、又はそれらの変異体若しくは断片を含む、請求項1又は2に記載のバイオマーカーパネル。
- 前記セットが、バイオマーカーTSPAN13、GDNF、C2CD5、SUSD6、BCL2L2、PLK3、DYNLT3及びPLXNA3、又はそれらの変異体若しくは断片を含む又はからなる、請求項3に記載のバイオマーカーパネル。
- TSPAN13ポリペプチド又はそれをコードするmRNA、又はそれらの変異体若しくは断片を含む、細胞老化のバイオマーカー。
- 試験試料中の老化細胞を検出する方法であって、
該方法は、該試料中で、少なくとも請求項1〜5のいずれか一項に記載の老化細胞バイオマーカーのセット又はバイオマーカーの発現を検出することを含み、ここで参照試料中で検出された発現レベルと比較した少なくとも1つの該バイオマーカーの発現レベルの変化が、該試料中に存在する老化細胞の指標である、方法。 - 参照試料中で検出された発現レベルと比較した、TSPAN13、GDNF、C2CD5、PLXNA3、SUSD6、BCL2L2及び/又はPLK3、又はそれらの変異体若しくは断片の発現レベルの上昇が、該試料中に存在する老化細胞の指標である、請求項6に記載の方法。
- 前記試験試料が被験体から採取された体試料であり、又は該試料が、血液、血漿、血清、髄液、尿、汗、唾液、涙、乳房吸引液、前立腺液、精液、膣液、糞便、子宮頸管掻爬、細胞、羊水、眼内液、粘液、息の水分、動物組織、細胞溶解物、腫瘍組織、髪、皮膚、腔内粘膜、爪、骨髄、軟骨、プリオン、骨粉末、耳垢、又はそれらの組み合わせを含む、請求項6又は7に記載の方法。
- 前記被験体が、実験動物又はヒトである、請求項6〜8のいずれか一項に記載の方法。
- 試料中の老化細胞を検出するための老化細胞検出キットであって、
該キットは、少なくとも請求項1〜4のいずれか一項に記載のバイオマーカーパネル又は請求項5に記載のバイオマーカーを含む、キット。 - 少なくとも1つの対照試料又は参照試料を含む、若しくは陰性対照及び/又は陽性対照を含む、請求項10に記載のキット。
- 老化細胞を殺傷するための薬物複合体であって、該複合体は、
(i)使用中に、TSPAN13、GDNF、FAM214B、PLXNA3、SUSD6、TOLLIP、ZBTB7A、B4GALT7、BCL2L2、CHMP5、DDA1、DYNLT3、NOL3、PDLIM4、PLK3、RAI14、SCOC、SLC16A3、TAF13、TMEM87B、UFM1及びZNHIT1からなる群から選択される少なくとも1つの老化細胞バイオマーカーに特異的に標的化及び結合するように構成された老化細胞標的化剤と、又はここで該標的化剤がTSPAN13、PLXNA3、SUSD6、GDNF、FAM214B、TOLLIP and ZBTB7Aからなる群から選択されるバイオマーカーに結合する、並びに
(ii) 結合した老化細胞を殺傷する細胞毒性剤とを含む、薬物複合体。 - 使用時に、TSPAN13に特異的に標的化及び結合するように構成された標的化剤を含む、請求項12に記載の薬物複合体。
- 前記標的化剤が、抗体若しくはその抗原結合断片、アプタマー、プラスチック抗体又は小分子である、請求項12又は13に記載の薬物複合体。
- 前記細胞毒性剤が、老化細胞抑制剤、放射性同位元素、毒素又は毒性ペプチドであり、若しくは老化細胞抑制剤である、請求項12〜14のいずれか一項に記載の薬物複合体。
- 前記細胞毒性が、(a)Bcl-2抗アポトーシスタンパク質ファミリーメンバーの阻害剤、(b)MMD2阻害剤、又は(c)Akt特異的阻害剤、若しくは1以上のBCL-2抗アポトーシスタンパク質ファミリーメンバーの阻害剤であり、ここで該阻害剤が少なくともBcl-xLを阻害し、又はABT-263、ABT-737、WEHI-539、及びA-1 155463から選択される、請求項15に記載の薬物複合体。
- 医薬品として使用するための、請求項12〜16のいずれか一項に記載の薬物複合体。
- 加齢性疾患の治療、遅延、予防又は改善における使用のための、請求項12〜17のいずれか一項に記載の薬物複合体であって、又は該加齢性疾患がアテローム性動脈硬化症、循環器疾患、癌、関節炎、緑内障、白内障、骨粗鬆症、2型糖尿病、高血圧症、アルツハイマー病又は他のタイプの認知症である、薬物複合体。
- 請求項12〜16のいずれか一項に記載の薬物複合体と、薬学的に許容される溶媒とを含む、医薬組成物。
- 非老化細胞よりも老化細胞を選択的に殺傷する、請求項12〜16のいずれか一項に記載の薬物複合体を含む医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17160165 | 2017-03-09 | ||
EP17160165.1 | 2017-03-09 | ||
PCT/NL2018/050148 WO2018164580A1 (en) | 2017-03-09 | 2018-03-09 | Biomarkers for cellular senescence |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020511674A JP2020511674A (ja) | 2020-04-16 |
JP2020511674A5 true JP2020511674A5 (ja) | 2021-03-04 |
Family
ID=58266455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019571199A Pending JP2020511674A (ja) | 2017-03-09 | 2018-03-09 | 細胞老化バイオマーカー |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200041492A1 (ja) |
EP (1) | EP3593134A1 (ja) |
JP (1) | JP2020511674A (ja) |
CN (1) | CN110678751A (ja) |
WO (1) | WO2018164580A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111257565A (zh) * | 2018-12-03 | 2020-06-09 | 上海细胞治疗集团有限公司 | 一种衰老细胞的检测试剂盒及其检测方法 |
CN111366736A (zh) * | 2020-03-31 | 2020-07-03 | 中国科学院昆明动物研究所 | 指征健康衰老关键通路的血清蛋白质标志物及应用 |
KR20220056730A (ko) * | 2020-10-28 | 2022-05-06 | 의료법인 성광의료재단 | Abt263을 유효성분으로 포함하는 디스크 질환 예방 및 치료용 조성물 |
CN112359103B (zh) * | 2020-11-10 | 2023-03-14 | 中国科学院动物研究所 | 人皮肤衰老的分子标志物和调控靶标及其应用 |
CN112891358B (zh) * | 2020-11-19 | 2023-05-12 | 苏州正永生物医药有限公司 | Bcl-2抑制剂的应用及治疗衰老相关皮肤病的药物组合物 |
EP4163379A1 (en) * | 2020-12-22 | 2023-04-12 | Institute Of Zoology, Chinese Academy Of Sciences | Method for identifying and/or regulating senescence |
CN113652491A (zh) * | 2021-02-02 | 2021-11-16 | 暨南大学 | m6A RNA甲基化含量及其甲基化相关酶和结合蛋白在制备衰老检测试剂盒中的应用 |
CN114524872A (zh) * | 2022-03-09 | 2022-05-24 | 广州诺诚生物技术研发有限公司 | 一种用于乳腺癌检测的单克隆抗体及其试剂盒 |
WO2023238845A1 (ja) * | 2022-06-07 | 2023-12-14 | アステラス製薬株式会社 | 加齢疾患の治療又は予防のための抗インテグリンα11抗体を含む医薬組成物 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
JPH06506688A (ja) | 1991-04-10 | 1994-07-28 | バイオサイト・ダイアグノスティックス・インコーポレイテッド | クロストークインヒビターおよびその使用 |
DE69231382T2 (de) | 1991-04-12 | 2001-01-25 | Biosite Diagnostics Inc., San Diego | Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden |
US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
CN1484806A (zh) | 2000-07-18 | 2004-03-24 | �����弪��ϵͳ��˾ | 基于隐含模式用于从生物数据中识别生物状态的方法 |
US6890763B2 (en) | 2001-04-30 | 2005-05-10 | Syn X Pharma, Inc. | Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons |
CA2484625A1 (en) | 2002-05-09 | 2003-11-20 | Surromed, Inc. | Methods for time-alignment of liquid chromatography-mass spectrometry data |
KR100947738B1 (ko) * | 2007-08-28 | 2010-03-17 | (주)아모레퍼시픽 | 피부 노화 진단 키트 및 피부 노화 진단 방법 |
AU2015203111B2 (en) * | 2008-02-01 | 2017-09-28 | The General Hospital Corporation | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
CN101999002A (zh) * | 2008-02-04 | 2011-03-30 | 彼帕科学公司 | 诊断和治疗parp-介导的疾病的方法 |
CA2745376A1 (en) * | 2008-12-01 | 2010-06-10 | Lifespan Extension Llc | Methods and compositions for altering health, wellbeing, and lifespan |
CA2754392A1 (en) * | 2009-03-11 | 2010-09-16 | Nestec S.A. | Tissue-specific aging biomarkers |
US10279018B2 (en) * | 2012-12-03 | 2019-05-07 | Unity Biotechnology, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
GB201409519D0 (en) * | 2014-05-29 | 2014-07-16 | Univ Leicester | Senescent cell biomarkers |
US20190262399A1 (en) * | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
-
2018
- 2018-03-09 CN CN201880030418.3A patent/CN110678751A/zh active Pending
- 2018-03-09 JP JP2019571199A patent/JP2020511674A/ja active Pending
- 2018-03-09 US US16/492,410 patent/US20200041492A1/en not_active Abandoned
- 2018-03-09 WO PCT/NL2018/050148 patent/WO2018164580A1/en unknown
- 2018-03-09 EP EP18710575.4A patent/EP3593134A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020511674A5 (ja) | ||
Childs et al. | Senescent cells: an emerging target for diseases of ageing | |
Nascimento-Ferreira et al. | Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado–Joseph disease | |
Shao et al. | SUMO1 SUMOylates and SENP3 deSUMOylates NLRP3 to orchestrate the inflammasome activation | |
Zhou et al. | Interleukin-1β and tumor necrosis factor-α augment acidosis-induced rat articular chondrocyte apoptosis via nuclear factor-kappaB-dependent upregulation of ASIC1a channel | |
Zhang et al. | Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate | |
Wang et al. | Progranulin is positively associated with intervertebral disc degeneration by interaction with IL-10 and IL-17 through TNF pathways | |
CN106456699A (zh) | 作为抗老化剂抑制抗凋亡的Bcl‑2蛋白的组合物和方法 | |
Feng et al. | Protein profile in HBx transfected cells: a comparative iTRAQ-coupled 2D LC-MS/MS analysis | |
Pomorska-Mól et al. | Immune and inflammatory response in pigs during acute influenza caused by H1N1 swine influenza virus | |
Xia et al. | SARS-CoV-2 N protein induces acute lung injury in mice via NF-ĸB activation | |
JP2007521015A5 (ja) | ||
Galindo-Moreno et al. | Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein | |
Zhou et al. | Morroniside attenuates nucleus pulposus cell senescence to alleviate intervertebral disc degeneration via inhibiting ROS-Hippo-p53 pathway | |
Yang et al. | SIRT7 interacts with TEK (TIE2) to promote adriamycin induced metastasis in breast cancer | |
Liu et al. | „Cerebral dopamine neurotrophic factor “schützt H9c2-Kardiomyozyten vor Apoptose | |
Zeng et al. | IRF-8 is Involved in Amyloid-β 1–40 (Aβ 1–40)-induced Microglial Activation: a New Implication in Alzheimer’s Disease | |
Gonçalves et al. | Leptin, its receptor and aromatase expression in deep infiltrating endometriosis | |
Wyrębska et al. | Anticancer Activity of New Synthetic α‐Methylene‐δ‐Lactones on Two Breast Cancer Cell Lines | |
Lee et al. | Overexpression of TDP-43 causes partially p53-dependent G2/M arrest and p53-independent cell death in HeLa cells | |
Gao et al. | Japanese encephalitis virus induces apoptosis by activating the RIG-1 signaling pathway | |
Boucher et al. | Quantifying caspase-1 activity in murine macrophages | |
O’Flaherty et al. | Signaling through the TRAIL receptor DR5/FADD pathway plays a role in the apoptosis associated with skeletal myoblast differentiation | |
Liao et al. | ERα inhibited myocardin-induced differentiation in uterine fibroids | |
Zhu et al. | Protective effects of mild hypothermia against hepatic injury in rats with acute liver failure |